Details of the Drug Combination

General Information of Drug Combination (ID: DCG5YN6)

Drug Combination Name
Paromomycin Miltefosine
Indication
Disease Entry Status REF
Visceral Leishmaniasis Phase 3 [1]
Component Drugs Paromomycin   DM1AGXN Miltefosine   DMND304
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Paromomycin
Disease Entry ICD 11 Status REF
Amoebiasis 1A36 Approved [2]
Hepatic coma N.A. Approved [2]
Intestinal amebiasis 1A36 Approved [3]
Paromomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [7]
------------------------------------------------------------------------------------
Paromomycin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Expression [8]
------------------------------------------------------------------------------------
Indication(s) of Miltefosine
Disease Entry ICD 11 Status REF
Chronic urticaria N.A. Approved [4]
Leishmaniasis 1F54 Approved [5]
Visceral leishmaniasis 1F54.0 Phase 2 [6]
Miltefosine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Phospholipase A2 (PLA2G1B) TT9V5JH PA21B_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Miltefosine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Choline phosphatase 1 (PLD1) DEB2ZMT PLD1_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
Miltefosine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Response To Substance [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03129646) Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
2 Paromomycin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064171.
4 Miltefosine FDA Label
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6 Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
7 Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
8 Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.
9 Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S17-20.
10 MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer. 2001 May 18;84(10):1405-11. doi: 10.1054/bjoc.2001.1776.